IDH2 and acute myeloid leukemia: Enasidenib has also been studied as a as a single-agent in R/R IDH2-mutated AML; it was tested in a phase 3, randomized IDHentify trial, producing a higher overall response rate (41% ensidenib versus 11% conventional care regimen), but with a disappointing OS result (6.8 months enasidenib versus 6.2 months conventional care regimen) [51].